Chemomab Therapeutics Ltd ADR CMMB
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- $1.83
- Day Range
- $1.67–1.84
- 52-Week Range
- $1.35–4.92
- Bid/Ask
- $1.69 / $1.84
- Shares Outstanding
- 7.33M
- Market Cap
- $12.75M
- Volume/Avg
- 176,793 / 114,748
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Chemomab Therapeutics Ltd is a clinical-stage biotechnology company, focusing on the discovery and development of therapeutics for fibrosis-related diseases with large unmet needs. The company's candidate, CM-101, is a monoclonal antibody that targets CCL24 and was shown to interfere with the underlying biology of liver, skin, and lung fibrosis using a novel and differentiated mechanism of action. CM-101 has demonstrated the potential to treat multiple severe and life-threatening fibrotic and inflammatory diseases.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- —
- Total Number of Employees
- 12
- Website
- https://www.chemomab.com
Valuation
|
Metric
|
CMMB
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 1.86 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
CMMB
Financial Strength
|
Metric
|
CMMB
|
|---|---|
Quick Ratio | 10.31 |
Current Ratio | 10.31 |
Interest Coverage | — |
Quick Ratio
CMMB
Profitability
|
Metric
|
CMMB
|
|---|---|
Return on Assets (Normalized) | −60.10% |
Return on Equity (Normalized) | −68.49% |
Return on Invested Capital (Normalized) | −72.56% |
Return on Assets
CMMB
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|Tr@W&vx | LOCK|BfPZ^ | $123B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|W^<L$% | LOCK|##lJ | $70B | |||
| argenx SE ADR
ARGX
| LOCK|P!?$&h | LOCK|#J | $54B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|<<Sb@Y | LOCK|@&SH! | $40B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|&N&<%sj | LOCK|?KQ | $36B | |||
| Moderna Inc
MRNA
| LOCK|K$HRL#V | LOCK|K^T | $27B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|cY#z$!% | LOCK|fs%?? | $25B | |||
| Incyte Corp
INCY
| LOCK|C#J?@CZ | LOCK|HV | $23B | |||
| BioNTech SE ADR
BNTX
| LOCK|jJ%B@q? | LOCK|N# | $23B | |||
| BridgeBio Pharma Inc
BBIO
| LOCK|&$j^tH | LOCK|?%> | $17B |
United States